CyberKnife radiotherapy for malignant fibrous histiocytoma of the chest wall: A case report and review of the literature

Wang,Zhen; Wu,Xin‑Hu; Li,Bing; Kong,Qing‑Tao; Shen,Ze‑Tian; Li,Jing; Liu,Zhi‑Bing; Zhu,Xi‑Xu

doi:10.3892/ol.2014.1995

CyberKnife radiotherapy for malignant fibrous histiocytoma of the chest wall: A case report and review of the literature

Authors:
- Zhen Wang
- Xin‑Hu Wu
- Bing Li
- Qing‑Tao Kong
- Ze‑Tian Shen
- Jing Li
- Zhi‑Bing Liu
- Xi‑Xu Zhu
View Affiliations

Affiliations: Department of Radiation Oncology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, P.R. China, Department of Dermatology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, P.R. China
Published online on: March 24, 2014 https://doi.org/10.3892/ol.2014.1995
Pages: 1877-1880

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant fibrous histiocytoma (MFH) is the most common type of soft tissue sarcoma, but rarely originates in the chest wall. Surgical resection is considered to be the most reliable treatment, however, no consensus has been reached concerning the best treatment for unresectable MFH. The current study presents the case of a 77‑year‑old male with MFH of the chest wall. The patient developed a painless mass and intermittent fever over a four‑month period. A computed tomography scan demonstrated a large inhomogeneous lesion in the right chest wall, which was subsequently diagnosed via biopsy as a MFH. Since the tumor was an unresectable mass, CyberKnife® radiotherapy was conducted. Following the treatment, a marked reduction in the tumor size was observed with a tolerable level of toxicity. The sequencing analysis also revealed an in‑frame deletion (delE746‑A750) in exon 19 of the epidermal growth factor receptor gene. Based on this result, gefitinib was administered to the patient at a dose of 250 mg/day.

View Figures

View References

1	O’Brien JE and Stout AP: Malignant fibrous xanthomas. Cancer. 17:1445–1455. 1964.
2	Yoshida N, Miyanari N, Yamamoto Y and Egami H: Successful treatment of malignant fibrous histiocytoma originating in the chest wall: report of a case. Surg Today. 36:714–721. 2006. View Article : Google Scholar
3	Shikada Y, Yoshino I, Fukuyama S, Kameyama T and Maehara Y: Completely wide resection of malignant fibrous histiocytoma of the chest wall: expect for long survival. Ann Thorac Cardiovasc Surg. 12:141–144. 2006.PubMed/NCBI
4	Raut CP and Pisters PW: Retroperitoneal sarcomas: Combined-modality treatment approaches. J Surg Oncol. 94:81–87. 2006. View Article : Google Scholar : PubMed/NCBI
5	Mintz A and Heron DE: CyberKnife(R) robotic stereotactic radiosurgery and stereotactic body radiation therapy. Technol Cancer Res Treat. 9:539–540. 2010. View Article : Google Scholar : PubMed/NCBI
6	Cox JD, Stetz J and Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
7	Al-Agha OM and Igbokwe AA: Malignant fibrous histiocytoma: between the past and the present. Arch Pathol Lab Med. 132:1030–1035. 2008.PubMed/NCBI
8	Anagnostopoulos G, Sakorafas GH, Grigoriadis K and Kostopoulos P: Malignant fibrous histiocytoma of the liver: a case report and review of the literature. Mt Sinai J Med. 72:50–52. 2005.PubMed/NCBI
9	Sawai H, Kamiya A, Kurahashi S, Yamanaka Y and Manabe T: Malignant fibrous histiocytoma originating from the chest wall: report of a case and collective review of cases. Surg Today. 28:459–463. 1998. View Article : Google Scholar : PubMed/NCBI
10	O’Sullivan P, O’Dwyer H, Flint J, Munk PL and Muller N: Soft tissue tumours and mass-like lesions of the chest wall: a pictorial review of CT and MR findings. Br J Radiol. 80:574–580. 2007.PubMed/NCBI
11	Abe T, Yamanaka K, Nakata W, Mori N, Sekii K, Yoshioka T and Itatani H: A case of retroperitoneal malignant fibrous histiocytoma with marked response to concurrent cisplatin and radiation therapy: a case report. Hinyokika Kiyo. 53:241–246. 2007.(In Japanese).
12	Lehnhardt M, Daigeler A, Homann HH, Schwaiberger V, Goertz O, Kuhnen C and Steinau HU: MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities - an analysis of 140 patients. Langenbecks Arch Surg. 394:313–320. 2009. View Article : Google Scholar
13	Mauri D, Panou C, Valachis A, Kamposioras K and Tsali L: Tyrosine kinase inhibitors in treatment of fibrous histiocytoma. Exp Oncol. 31:60–61. 2009.PubMed/NCBI
14	Gutierrez JC, Perez EA, Franceschi D, Moffat FL Jr, Livingstone AS and Koniaris LG: Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res. 141:105–114. 2007. View Article : Google Scholar : PubMed/NCBI
15	Nagano H, Deguchi K and Kurono Y: Malignant fibrous histiocytoma of the bucca: a case report. Auris Nasus Larynx. 35:165–169. 2008. View Article : Google Scholar : PubMed/NCBI